# A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization

> **NCT03250377** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 207 (actual)

## Conditions studied

- Partial Seizures With or Without Secondary Generalization
- Epilepsy

## Interventions

- **DRUG:** Brivaracetam

## Key facts

- **NCT ID:** NCT03250377
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-05
- **Primary completion:** 2024-12-24
- **Final completion:** 2024-12-24
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250377, "A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03250377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*